logo for news

PSEDM Life with insulin Programs

by: Jeremy F. Robles, MD, FPCP, FPSEDM

In the past years the PSEDM has worked closely with various partners to provide a meaningful and sustainable way to support several diabetic indigents patients. Matched by the commitment of the Filipino Endocrinologists serving Filipino people we have successfully adopted 60 diabetic patients throughout the country. Free insulin and supplies are given through their respective doctors in the current programs. The doctors follow these patients closely and monitor them through a centralized data system.

The 3 Programs

PSEDM – International Diabetes Federation – Life for a Child (IDF-LFAC)

The International Diabetes Federation through the Life for a Child (LFAC) program was established in the 2000. Its vision is “No child should die of Diabetes” with the mission to provide support through the best possible healthcare available, to all young people with diabetes in developing countries. The Philippines is one of the countries that have received support from the program under the leadership of Dr. Rosa Allyn Sy in 2001, 23 patients were enrolled under 3 centers (ISDFI – Institute for the Study of Diabetes Foundation Incorporated, UP-PGH Section of Pediatric Endocrinology and the Philippine Centre for Diabetes Education Foundation (PCDEF)/ Diabetes Care). HOPE Worldwide Foundation became the monitoring arm of IDF-LFAC Philippines. More than a hundred patients were provided with insulin, syringes, glucose monitors and education materials between 2001 to 2013. In 2013, the Philippine Society of Endocrinology, Diabetes & Metabolism (PSEDM) became the newest partner of IDF-LFAC Philippines. Ten patients are currently supported by IDF-LFAC program with PSEDM.

PSEDM – Multicare Help for Insulin Program (HIP)
PSEDM – Novo Nordisk Changing Diabetes for Life Program ( PNNCDLife )
PSEDM – GETZ Pharma

Pharmaceutical companies have also contributed significantly to the realization of these projects. Multicare Pharmaceutical Philippines under the Help for Insulin Program (HIP) started in May 2014 with patients receiving their initial medications and kits. In july 2014, Novo Nordisk Philippines also began providing free insulin to patients enrolled in the PNNCDLife Program. Getz Pharma joined in 2015 providing insulin for the Mindanao region. A total of 60 patients are currently receiving insulin and supplies from the different programs with PSEDM. Majority of the patients are located in Luzon and a few in the Visayas region.

Nomination & requirements for inclusion

The process begins with a nomination of a patient through a PSEDM member. You can send the request though the PSEDM secretariat indicating your nomination together with a short clinical summary and supporting papers. The general requirements are as follows:

1.) Patients should be a Filipino citizen.

2.) Patients should require Insulin for the maintenance & prevention of diabetes complications.

3.) Patient should be duly certified to be indigent by the Barangay of residence.

4.) Patient should be nominated by a PSEDM member and approved by the PSEDM Board.

5.) Participating doctor will be asked to submit reports of the progress of the patient.

Other specific requirements may be needed for the various Insulin support programs.

We extend the heartfelt thanks of all the patients and doctors that are involved with this noble project. We are encouraging everyone to get involved. PSEDM will continue to support the Filipino diabetic patient because we believe we can make a difference 1 patient at a time.

Philippine Endocrine Researches

Search

 

Keyword (E.g. thyroid, lipid, diabetes…)

 

Author (Lastname)

 

Year (Publication)


psem_logo_small

Position Statement of the Philippine Society of Endocrinology and Metabolism (PSEM) regarding the Use of Stem Cell Therapy for Diabetes Mellitus

So the public may know

 

In the last few months, proponents of stem cell therapy have issued statements to the media regarding the supposed efficacy of this approach for diabetes mellitus with claims that it can normalize blood sugars within 2 months or at least decrease the number of anti-diabetic medications.

The Philippine Society of Endocrinology and Metabolism (PSEM) would like to warn the public that there is NO cure for diabetes mellitus and that at the moment stem cell therapy is an experimental treatment for both Type 1 and Type 2 diabetes. There is as yet, no conclusive evidence that stem cell therapy is effective and safe for diabetes.

As such, stem cell therapy cannot be made available to individuals with diabetes, as a standard treatment like the usual drug prescriptions but rather, any patient who is receiving stem cell therapy for diabetes should receive it only under controlled conditions such as under experimental protocols of clinical trials. Patients receiving stem cell therapy under clinical trials should NOT pay for these experimental treatments and must sign an informed consent that explains the procedure, its benefits and possible harms. All clinical trials also need to be registered with and approved by the Food and Drug Administration (FDA) before implementation.

While it is true that stem cell therapy is labeled as promising in many reviews of its use in both Type 1 and Type 2 diabetes, it is still a science that is in in its infancy and much is not yet known about its use. Like many emerging therapies, “side effects and long-term safety must be determined, since transplanted cells may remain for many years in patients’ bodies. Therefore, careful monitoring and extended follow-up of patients who receive stem cell treatments is extremely important.” [www.isscr.org- International Society for Stem Cell Research (ISSCR) Patient Handbook].

We therefore, urge the public to refrain from availing of stem cells for the therapy of diabetes. Its use in diabetes mellitus can only be justified by research in the setting of clinical trials. Any patient who is being offered this form of therapy for diabetes should first ensure that a specialist in the treatment of diabetes is seeing them and that they are in fact being enrolled in a clinical trial. They should also verify with the FDA if such a trial is registered and approved by this agency.

Please report to the FDA any of the following:

1. Use of stem cell therapy by persons or institutions not accredited by FDA;
2. Use of stem cell therapy for diabetes mellitus outside of a clinical trial or as actual treatment;
3. Acceptance of payment for stem cell therapy when used for diabetes mellitus

Please report the above to (02) 9102253 or the FDA website: report@fda.gov.ph